Steven Perrin, Ph.D.

Chief Executive Officer, ALS Therapy Development Institute (ALS TDI), Cambridge, MA 

Steven Perrin, Ph.D., is the chief executive officer and chief scientific officer at the ALS Therapy Development Institute (ALS TDI) in Cambridge, Massachusetts. He earned his doctoral degree in biochemistry from Boston University Medical Center. Dr. Perrin moved into the pharmaceutical industry in 1997, holding positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals in Cambridge and served as the Director of Molecular Profiling at Biogen Idec in Cambridge. He joined ALS TDI in 2007 as part of an historical collaboration between the Muscular Dystrophy Association, Augie's Quest and ALS TDI with the goal of developing a center ofexcellence for ALS drug development and translational research for neurodegenerative diseases. Under Dr. Perrin’s leadership, ALS TDI has assembled a scientific team that has brought two potential treatments into clinical development for ALS in the last seven years.